Bioventus Inc. BVS
We take great care to ensure that the data presented and summarized in this overview for Bioventus Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BVS
View all-
Essex Woodlands Management, Inc. The Woodlands, TX13MShares$82.9 Million19.68% of portfolio
-
Juniper Investment Company, LLC New York, NY6.83MShares$43.5 Million18.22% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT5.81MShares$37 Million1.94% of portfolio
-
Sv Health Investors, LLC Boston, MA1.49MShares$9.48 Million32.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.22MShares$7.76 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny549KShares$3.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$3.39 Million0.0% of portfolio
-
Morgan Stanley New York, NY445KShares$2.83 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA425KShares$2.71 Million0.0% of portfolio
-
Jane Street Group, LLC New York, NY385KShares$2.45 Million0.0% of portfolio
Latest Institutional Activity in BVS
Top Purchases
Top Sells
About BVS
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Insider Transactions at BVS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 21
2024
|
Katrina J Church SVP & Chief Compliance Officer |
SELL
Open market or private sale
|
Direct |
2,559
-5.85%
|
$12,795
$5.57 P/Share
|
Jun 21
2024
|
Anthony D'Adamio SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
5,904
-5.82%
|
$29,520
$5.57 P/Share
|
Jun 21
2024
|
Mark Leonard Singleton SVP & CFO |
SELL
Open market or private sale
|
Direct |
9,219
-9.8%
|
$46,095
$5.57 P/Share
|
Jun 20
2024
|
Katrina J Church SVP & Chief Compliance Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,600
+16.43%
|
-
|
Jun 20
2024
|
Anthony D'Adamio SVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
19,850
+16.36%
|
-
|
Jun 20
2024
|
Mark Leonard Singleton SVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,000
+24.78%
|
-
|
Jun 17
2024
|
Katrina J Church SVP & Chief Compliance Officer |
SELL
Open market or private sale
|
Direct |
8,759
-19.94%
|
$43,795
$5.84 P/Share
|
Jun 17
2024
|
Anthony D'Adamio SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
11,308
-12.17%
|
$56,540
$5.84 P/Share
|
Jun 17
2024
|
Mark Leonard Singleton SVP & CFO |
SELL
Open market or private sale
|
Direct |
13,753
-17.89%
|
$68,765
$5.84 P/Share
|
Jun 16
2024
|
Pat Beyer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
965
+1.9%
|
-
|
Jun 16
2024
|
Mary Kay Ladone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,814
+3.34%
|
-
|
Jun 16
2024
|
Michelle Mc Murry Heath Director |
BUY
Exercise of conversion of derivative security
|
Direct |
386
+0.79%
|
-
|
Jun 15
2024
|
Katrina J Church SVP & Chief Compliance Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,875
+37.96%
|
-
|
Jun 15
2024
|
Anthony D'Adamio SVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
34,696
+27.18%
|
-
|
Jun 15
2024
|
Mark Leonard Singleton SVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
42,202
+35.44%
|
-
|
Jun 07
2024
|
Mary Kay Ladone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,400
+37.5%
|
-
|
Jun 07
2024
|
William A Hawkins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,400
+11.61%
|
-
|
Jun 07
2024
|
Guido J Neels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,400
+34.1%
|
-
|
Jun 07
2024
|
Guy P Nohra Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,400
+23.29%
|
-
|
Jun 07
2024
|
Susan M Stalnecker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,400
+27.67%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 506K shares |
---|---|
Open market or private purchase | 394K shares |
Other acquisition or disposition | 41.4K shares |
Open market or private sale | 70.2K shares |
---|